Ipsen (FR:IPN) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ipsen has secured exclusive global rights to BMX-502, a promising preclinical T-cell engager developed by Biomunex, aiming to harness MAIT cells for cancer treatment. This innovative bispecific antibody targets MAIT cells and the tumor antigen GPC3, potentially offering a more effective and safer therapy for solid tumors. Ipsen will handle clinical development and commercialization, while Biomunex stands to receive up to $610 million through various payments and royalties.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.